Back to search

University of Leeds

Reprogramming of myeloid progenitors by the BCR-ABL oncogene

Abstract

dc:description.abstract

The constitutive tyrosine kinase activity of the BCR-ABL oncogene is central for the pathogenesis of chronic myeloid leukaemia (CML). Clinical treatment of CML with the kinase inhibitor Imatinib Mesylate (IM) is a fundamental success demonstrating disease addiction upon BCR-ABL activity. However, 15-20% of CML patients develop drug resistance leading to patient fatality. The most studied mechanism of IM-resistance is point mutations within the kinase domain of BCR-ABL. However, these account for ~40% of patients crafting the challenge in understanding how leukaemic cells can survive in the absence of BCR- ABL activity. To address this issue, a preclinical model of CML drug resistance was established using KCL22 cells (Chapter 3). Single cell clones were generated and drug resistant derivatives established which had (i) no mutations within BCR-ABL and (ii) functional IM pharmacokinetics with reduction in the phosphorylation of STAT5 and CrkL. Being kinase-independent, are other domains of BCR-ABL compensating to maintain the leukaemic state or is BCR-ABL now redundant? To address this, the consequence of BCR-ABL depletion was explored (Chapter 4). In contrast to the original parental KCL22 cells, the drug-resistant clones continued to survive and expand upon the loss of BCR-ABL, supporting the proposal of ‘oncogene independence’ as a novel mechanism to escape drug targeting. Genome-wide expression analysis identified the induction of the RUNX1 transcription factor upon drug resistance. As RUNX1 is deregulated is several haematological malignancies, its potential role in drug resistant CML was explored (Chapter 5). Targeting of RUNX1 within drug resistant cells resulted in the failure of these cells to grow associated with the acquisition of a macrophage-like phenotype. The work herein identifies oncogene independence as a novel mechanism for establishing drug resistant CML with RUNX1 functioning as new oncogenic driver to compensate for the loss of BCR-ABL and presenting itself as a new therapeutic target.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2017

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bheeshmachar, Geetha
Advisor dc:contributor.advisor
  • Laslo, Peter

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.739770

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Bheeshmachar, Geetha. Reprogramming of myeloid progenitors by the BCR-ABL oncogene. doctoral thesis, University of Leeds, 2017.